Journal article
Authors list: Bschleipfer, T.; Wagenlehner, F. M.; Luedecke, G.; Pilatz, A.; Weidner, W.
Publication year: 2013
Pages: 800-804
Journal: Urologe A
Volume number: 52
Issue number: 6
ISSN: 0340-2592
eISSN: 1433-0563
DOI Link: https://doi.org/10.1007/s00120-013-3153-1
Publisher: Springer
Abstract:
The prevalence of overactive bladder syndrome (OAB) increases with age and is associated with a clear reduction in patient quality of life. Age-related alterations of the urinary bladder as well as increased occurrence of neurological and non-neurological diseases with age contribute to the onset of OAB. Antimuscarinic drugs are the medication of choice; however, restricted tolerability and polypharmacotherapy limit administration in the elderly. Extended release preparations are to be favored as constant intake of medication is more feasible and adverse effects occur less often compared to immediate release formulations. With respect to cognitive impairment newly introduced substances and quaternary amines seem to be advantageous. However, constipation remains a notable side effect in older patients. Intravesical botulinum toxin type A (BoNT/A) injections are an alternative and a therapeutic escalation in patients suffering from OAB. Adverse events are very rare and drug interactions are unknown; however, injections can result in hypercontinence causing the necessity for artificial urine drainage.
Citation Styles
Harvard Citation style: Bschleipfer, T., Wagenlehner, F., Luedecke, G., Pilatz, A. and Weidner, W. (2013) Overactive bladder in the elderly, Urologe A, 52(6), pp. 800-804. https://doi.org/10.1007/s00120-013-3153-1
APA Citation style: Bschleipfer, T., Wagenlehner, F., Luedecke, G., Pilatz, A., & Weidner, W. (2013). Overactive bladder in the elderly. Urologe A. 52(6), 800-804. https://doi.org/10.1007/s00120-013-3153-1
Keywords
Antimuscarinics; Bladder, overactive; Botulinum toxin type A; DETRUSOR; DOUBLE-BLIND; ETIOLOGY; EXTENDED-RELEASE; OLDER; OXYBUTYNIN; URINARY-INCONTINENCE